Zimbabwe has rejected a substantial US health deal worth $367m (272 million pounds) over five years because of Washington's insistence on confidential information.
The decision became public following a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesman has since clarified that the US was demanding access to genetic material for scientific study and commercial gain but was unwilling to share the benefits from any future medical innovations.
"We must now begin the challenging and unfortunate process of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for continued negotiations to find a deal agreeable to both sides so the nation's vital HIV programme can be sustained.
Broader Background
This rejection follows a similar case in neighbouring Kenya, where a high court suspended a related deal with the US after concerns were raised about the safety of citizens' health data.
After resuming office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral agreements to boost openness and responsibility.
Based on reports, 16 nations in Africa have to date agreed to similar health pacts, constituting over $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation would have delivered significant advantages for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment through American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, without any corresponding promise of benefiting from any medical innovations – like new medicines or tests – that might result from that shared data," his statement read.
"Put simply, our nation would provide the basic resources for scientific discovery with no assurance that the final treatments would be available to our people if a new disease outbreak arise."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of bilateral deals were undermining frameworks already established through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework created to manage potential pandemics.
"This mechanism is designed to guarantee that when a country provides its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage further discussions with our US partners on how future co-operation might be designed in a manner that honours the independence and interests of both nations."
Health Experts Reaction
Medical experts expressed it understood the official position, but urged that talks should continue considering much of the country's HIV programmes relied on external financing.
"Where technical issues arise, such as those involving data governance or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," the group said.
This impasse emphasises the ongoing challenges between receiving vital international aid and safeguarding a country's data in an increasingly data-driven world.